Wed, Jun. 22, 12:42 PM
Wed, Jun. 22, 11:00 AM
Wed, Jun. 22, 9:24 AM
Wed, Jun. 22, 7:21 AM
- Thinly traded nano cap Pluristem Therapeutics (NASDAQ:PSTI) is up 11% premarket on light volume in response to its announcement of preclinical data that suggest its PLX-PAD cells may be effective in treating Duchenne muscular dystrophy.
- In a mouse model study, PLX-PAD cells reduced an enzyme called creatine phosphokinase (CPK), a marker of muscle degeneration or injury, by ~50% compared to placebo. In addition, analyses of tissue samples showed reduced levels of inflammation and necrosis (death of most of the cells in an organ or tissue) and evidence of regeneration of muscle tissue.
- PLX cells are mesenchymal-like adherent stromal cells derived from full term human placentas that may be administered without the need for HLA matching. According to the company, PLX-PAD (peripheral artery disease) cells have demonstrated the ability to stimulate the growth of new blood vessels in preclinical models inducing muscle tissue regeneration and improving muscle function.
- PLX-PAD is currently under development for the treatment of critical limb ischemia, intermittent claudication (leg cramps caused by the obstruction of arteries), muscle injury, pulmonary arterial hypertension and preeclampsia.
- DMD-related tickers: (NASDAQ:SRPT)(NASDAQ:BMRN)(NASDAQ:SMMT)(NASDAQ:PTCT)(NYSE:PFE)(OTCQB:MRNA)
Wed, Apr. 13, 9:16 AM
Mon, Feb. 22, 9:19 AM
Wed, Feb. 17, 1:22 PM
- Micro cap Pluristem Therapeutics (PSTI +27.4%) is up again today on a 3x surge in volume, adding to yesterday's 31% jump. Money flow has spiked in response to the news that NIH's National Institute of Allergy and Infectious Diseases (NIAID) will initiate studies in large animals to assess the company's PLX-R18 cell therapy as a medical countermeasure for the treatment of the hematologic aspects of acute radiation syndrome (ARS).
- Once the optimal dose is identified in large animals, a pivotal trial can be conducted which could support a Biologics License Application (BLA) under the Animal Rule approval pathway. Last September, the FDA confirmed that data from earlier NIAID trials were sufficient for the future design of PLX-R18 studies.
- The Animal Rule is an approval pathway for products that cannot meet the requirements for traditional licensure because efficacy studies in humans are not possible.
- Previously: Pluristem details development plan for second cell product (March 24, 2015)
Wed, Feb. 17, 12:45 PM
Wed, Feb. 17, 9:14 AM
Dec. 14, 2015, 9:21 AM
May 18, 2015, 9:15 AM
Feb. 17, 2015, 9:14 AM
Feb. 3, 2015, 12:47 PM
Feb. 2, 2015, 12:49 PM
Feb. 2, 2015, 9:12 AM
Feb. 2, 2015, 7:37 AM
- Last Wednesday, a bullish research report on thinly-traded micro cap Pluristem Therapeutics (NASDAQ:PSTI) propelled the stock almost 33% in two days.The report, by Acceleron Equity Research, stated a price target of $21, a seven-bagger from the then-current price of ~$3.
- Migdal Capital Markets senior biomedical analyst Steven Tepper says that investors don't have enough information about Acceleron to judge its credibility. "It would be irresponsible to make investment decisions on a research report that has no analyst name standing behind it. We need to know who owns this research company, who are the managers, what is its business model. A disclaimer means nothing if there's no analyst name written on the report."
- PSTI is down 12% premarket on mediocre volume.
- Previously: Pluristem surges on bullish research report (Jan. 28)
Pluristem Therapeutics, Inc. engages in the development of standardized cell therapy products for the treatment of life threatening diseases. Its patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and... More
Country: United States
Other News & PR